SENSITIZATION OF C6 GLIOMA TO CARBOPLATIN CYTOTOXICITY BY HYPERTHERMIA AND THYMIDINE

被引:34
作者
COHEN, JD
ROBINS, HI
JAVID, MJ
机构
[1] UNIV WISCONSIN, HOSP & CLIN, DEPT MED, MADISON, WI 53792 USA
[2] UNIV WISCONSIN, HOSP & CLIN, DEPT NEUROL, MADISON, WI 53792 USA
[3] UNIV WISCONSIN, HOSP & CLIN, DEPT NEUROL SURG, MADISON, WI 53792 USA
关键词
carboplatin; glioma; hyperthermia; thymidine;
D O I
10.1007/BF00167062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymidine (a nucleoside metabolite) and 41.8° C hyperthermia were used to sensitize C6 glioma cells to carboplatin cytotoxicity in vitro. Clinically achievable thymidine concentrations (0, 200, 400, or 1000 μg/ml × 24 hours) significantly enhanced carboplatin killing. Clinically achievable hyperthermia exposures (40.5 or 41.8° C x 1 hour) also enhanced carboplatin killing; 41.8° C was more effective than was 40.5° C. Thymidine and 41.8°C hyperthermia together enhanced carboplatin killing significantly more than did the thymidine-carboplatin or hyperthermia-carboplatin combinations. These results illustrate the concept of 'combination chemosensitization' for simultaneously addressing the divergent drug resistance mechanisms of malignant gliomas. © 1990 Kluwer Academic Publishers.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 56 条
[1]   HYPOXIA-MEDIATED NITRO-HETEROCYCLIC DRUGS IN THE RADIOTHERAPY AND CHEMOTHERAPY OF CANCER - AN OVERVIEW [J].
ADAMS, GE ;
STRATFORD, IJ .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (01) :71-76
[2]  
ALBRIGHT N, 1988, USERS GUIDE COMPUTER
[3]  
ANDREWS PA, 1988, CANCER RES, V48, P68
[4]   A SIMPLE AND REPRODUCIBLE EXPERIMENTAL INVIVO GLIOMA MODEL [J].
AUER, RN ;
DELMAESTRO, RF ;
ANDERSON, R .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1981, 8 (04) :325-331
[5]  
BLUMENREICH MS, 1984, CANCER RES, V44, P2203
[6]  
BROWN DM, 1983, CANCER RES, V43, P3138
[7]   EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
JONES, AC ;
MCELWAIN, TJ ;
RAJU, S ;
WILTSHAW, E ;
SMITH, IE ;
BAKER, JM ;
PECKHAM, MJ ;
HARRAP, KR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) :140-147
[8]  
CANETTA R, 1987, ONCOLOGY, V5, P61
[9]  
COHEN JD, 1987, CANCER RES, V47, P4335
[10]  
COHEN JD, 1988, CANCER RES, V48, P3576